HIVE vs NU

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 10, 2026

HIVE

70.4
AI Score
VS
NU Wins

NU

73.8
AI Score

Investment Advisor Scores

HIVE

Nov 10, 2026
70score
Recommendation
HOLD

NU

Nov 10, 2026
74score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric HIVE NU Winner
Forward P/E 62.8931 10.8342 NU
PEG Ratio 0 0.397 Tie
Revenue Growth 73.5% 52.1% HIVE
Earnings Growth -99.9% 66.3% NU
Tradestie Score 70.4/100 73.8/100 NU
Profit Margin -98.5% 42.7% NU
Beta 1.00 1.00 Tie
Implied Volatility N/A N/A Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

HIVE 1M: -28.3% · 3M: -37.2% NU 1M: -24.5% · 3M: -10.9%

Current Technical Phase

HIVE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -12.4%), weak momentum, RSI 34

RSI (14): 34.3 · Price: $1.72

NU

Markdown
Sell / avoid

Price below a falling SMA50 (slope -3.5%), weak momentum, RSI 39

RSI (14): 39.2 · Price: $12.08

Fundamentals Snapshot

Metric HIVE NU
Market Cap — —
Forward P/E -3.4 10.9
Trailing P/E — 16.9
Revenue (TTM) — —
Revenue Growth 0.7% 0.5%
Gross Margin 0.4% 1.0%
Operating Margin -0.6% 0.5%
EPS -1.32 0.73
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, NU is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.